CARLSBAD, Calif., June 10, 2021 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted
therapies, today announced that multiple presentations
highlighting advances in its ATTR amyloidosis programs will be
featured during the 2021 Peripheral Nerve Society (PNS) Annual
Meeting to be held virtually on June
12-13, and 25-27, 2021. Ionis' participation highlights the
advancements it's made in developing novel antisense therapies for
ATTR and underscores Ionis' commitment to this patient
community.
C. Frank Bennett, Ph.D., chief
scientific officer and franchise leader for neurological programs
at Ionis, is the featured plenary speaker to deliver the Arthur K.
Asbury Lecture. A founding member of Ionis, Dr. Bennett is
responsible for continuing to advance antisense technology and
expand Ionis' drug discovery platform. He will discuss the
therapeutic potential of antisense therapies to address an
unprecedented range of neurological diseases, with a focus on TTR
amyloidosis.
Kemi Olugemo, M.D., FAAN,
executive director, Ionis neurology clinical development, will
moderate a panel discussion on the changing landscape in the
treatment for TTR amyloidosis featuring panelists Nick Viney, executive director, clinical
development and project team leader for Ionis' NEURO-TTRansform
program and Sami Khella, M.D.,
professor and chief of neurology, Penn Presbyterian Medical
Center.
Ionis schedule of events and activities at PNS
- Friday, June 18 at
11 a.m. EDT/8
a.m. PDT
Platform panel discussion: A changing
landscape for a devastating disease - transthyretin amyloidosis, by
Nick Viney, executive director of
neurological clinical development at Ionis and Sami Khella, M.D.,
professor and chief of neurology, Penn Presbyterian Medical Center,
moderated by Kemi Olugemo, M.D.,
FAAN, executive director, Ionis neurology clinical development.
Registration is available here.
- Saturday, June 26 at
9:30 a.m. EDT/6:30 a.m. PDT
Arthur K. Asbury Lecture:
Antisense Therapies for Neurological Diseases by C. Frank Bennett, Ph.D., Ionis chief scientific
officer and franchise leader for neurological programs.
The following posters are available on-demand through the PNS
conference site.
- NEURO-TTRansform: Phase 3 Study to Evaluate Eplontersen in
Patients with hATTR-PN
- Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of
ION-682884, an Antisense Oligonucleotide in Development for
Transthyretin Amyloidosis
- Clinical Characteristics of Patients with Transthyretin Gene
Mutations and Polyneuropathy Manifestations of Hereditary
Transthyretin Amyloidosis
- Hereditary Transthyretin Amyloidosis and Other Neuromuscular
Diseases
- Efficacy and Safety With >3 Years of Inotersen Treatment for
Hereditary Transthyretin Amyloid Polyneuropathy (Encore)
- Diagnosis and Management of A Sibling Pair With Hereditary
Transthyretin Amyloidosis Associated With F44S (p.Phe64Ser)
Transthyretin Variant: A Case Report (Encore)
- Efficacy of Inotersen for Neuropathic Impairment Scores in
Patients with Hereditary Transthyretin Amyloidosis with
Polyneuropathy
Details on presentation times can be found on the PNS
website.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in
RNA-targeted therapy, pioneering new markets and changing standards
of care with its novel antisense technology. Ionis currently has
three marketed medicines and a premier late-stage pipeline
highlighted by industry-leading neurological and cardiometabolic
franchises. Our scientific innovation began and continues with the
knowledge that sick people depend on us, which fuels our vision of
becoming one of the most successful biotechnology companies.
To learn more about Ionis, visit www.ionispharma.com and
follow us on twitter @ionispharma.
Ionis' Forward-looking Statement
This press release includes forward-looking statements regarding
Ionis' business, financial guidance and the therapeutic and
commercial potential of Ionis' technologies and products in
development. Any statement describing Ionis' goals, expectations,
financial or other projections, intentions or beliefs is a
forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, including those related to the impact COVID-19 could
have on our business, and including but not limited to those
related to our commercial products and the medicines in our
pipeline, and particularly those inherent in the process of
discovering, developing and commercializing medicines that are safe
and effective for use as human therapeutics, and in the endeavor of
building a business around such medicines. Ionis' forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking statements.
Although Ionis' forward-looking statements reflect the good
faith judgment of its management, these statements are based only
on facts and factors currently known by Ionis. As a result, you are
cautioned not to rely on these forward-looking statements. These
and other risks concerning Ionis' programs are described in
additional detail in Ionis' annual report on Form 10-K for the year
ended December 31, 2020, and the most
recent Form 10-Q quarterly filing, which are on file with the SEC.
Copies of these and other documents are available from the
Company.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ionis-antisense-therapies-in-attr-amyloidosis-to-be-featured-at-2021-pns-annual-meeting-301310475.html
SOURCE Ionis Pharmaceuticals, Inc.